Date: 2014-05-31
Type of information: Presentation of results at a congress
phase: 1
Announcement: presentation of results at the 50th American Society of Clinical Oncology (ASCO) Annual Meeting, May 30 to June 3, 2014, in Chicago
Company: Genentech, a member of the Roche Group (USA - Switzerland) Seattle Genetics (USA - WA)
Product: DNIB0600A
Action
mechanism: antibody drug conjugate. DNIB0600A is an antibody drug conjugate consisting of an anti-NaPi2b monoclonal antibody conjugated to the cytotoxic agent MMAE using Seattle Genetics’ ADC technology.
Disease: non-small cell lung cancer, platinum-resistant ovarian cancer
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On May 31, 2014, Seattle Genetics announced data from several collaborator antibody-drug conjugate (ADC) programs presented at the American Society of Clinical Oncology(ASCO) 50th Annual Meeting being held May 30 to June 3, 2014 in Chicago, IL. Genentech, a member of the Roche Group, is presenting data from five ADC programs, including two oral presentations. A phase 1 clinical trial is being conducted by Genentech to evaluate the safety and activity of DNIB0600A in patients with non-small cell lung cancer (NSCLC) or platinum-resistant ovarian cancer (OC) (Abstract#2507). DNIB0600A is an ADC consisting of an anti-NaPi2b monoclonal antibody conjugated to the cytotoxic agent MMAE using Seattle Genetics’ ADC technology. In this analysis, 49 patients were evaluable (18 OC, 31 NSCLC) all treated at the recommended phase 2 dose level of 2.4 mg/kg every three weeks. DNIB0600A demonstrated antitumor activity with an encouraging safety profile. Confirmed partial responses were observed in 41 percent (seven of 17 patients) of IHC 2/3+ OC patients and 10 percent (two of 21 patients) of IHC 2/3+ NSCLC patients. Phase 1 studies in lung and ovarian cancer, and a phase 2 study in ovarian cancer are currently ongoing.
